Ratings Precise Biometrics AB Deutsche Boerse AG

Equities

PBC

SE0018013849

Market Closed - Deutsche Boerse AG Other stock markets 07:20:18 10/05/2024 BST			5-day change	1st Jan Change
0.1046 ^EUR	+8.28%		+0.19%	+12.47%

04-05	Precise Biometrics, Flowscape Expand Sales Distribution Deal	MT
04-05	Precise Biometrics Signs New Customer and Deepens Partnership with Flowscape Technology	CI

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 62% by 2026.
The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Electronic Equipment & Parts

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
PRECISE BIOMETRICS AB	+12.47%	9.64M		-
ORBBEC INC.	-28.95%	1.48B		-
PAPILON SAVUNMA TEKNOLOJI VE TICARET	+143.36%	138M	-	-
SUPREMA INC.	+30.22%	137M		-
NEXT BIOMETRICS GROUP ASA	+21.41%	83.01M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes